Allogene Therapeutics CAR-T Therapy Shows Promising Phase 2 Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Should l Buy ALLO?
Source: seekingalpha
- Significant Efficacy Improvement: In the pivotal phase 2 trial of the CAR-T therapy cema-cel, 58.3% of patients achieved minimal residual disease (MRD) negativity, compared to 16.7% in the observation arm, indicating a 41.6% absolute difference that highlights the therapy's substantial clinical potential in treating large B-cell lymphoma.
- ctDNA Levels Decline: At the first MRD assessment (day 45), the cema-cel group experienced a median plasma ctDNA reduction of 97.7%, while the observation cohort saw a median increase of 26.6%, showcasing cema-cel's superior efficacy in tumor marker clearance.
- Trial Progression: The trial is expected to complete enrollment by the end of 2027, with an interim event-free survival analysis projected for mid-2027 and a primary analysis in mid-2028, indicating the company's strategic planning in advancing CAR-T therapies.
- Positive Market Reaction: Following the encouraging clinical data, Allogene Therapeutics' stock surged approximately 46% in Monday morning trading, reflecting investor confidence in the future market potential of its CAR-T therapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALLO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALLO
Wall Street analysts forecast ALLO stock price to rise
11 Analyst Rating
10 Buy
0 Hold
1 Sell
Strong Buy
Current: 1.890
Low
5.00
Averages
8.50
High
14.00
Current: 1.890
Low
5.00
Averages
8.50
High
14.00
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Allogene Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: In a 24-patient analysis, cema-cel achieved a 58.3% MRD clearance rate compared to 16.7% in the observation arm, representing a significant 41.6% absolute difference, indicating a clear therapeutic advantage that could drive future clinical applications.
- Improved Financial Position: As of March 31, the company had $266.9 million in cash and cash equivalents, and in April, it raised approximately $200.4 million through a public offering, extending its cash runway into Q1 2029, thereby enhancing financial flexibility for R&D.
- Increased Expense Guidance: The forecast for operating cash expenses in 2026 has been raised from approximately $150 million to $165 million, with GAAP operating expenses expected to rise from $210 million to $225 million, reflecting confidence in future R&D investments while potentially impacting short-term financial performance.
- Safety and Tolerability: Management emphasized that no CRS, ICANS, or treatment-related hospitalizations were observed in ALLO-329 treatments, indicating feasibility in outpatient settings, which may attract more patients to participate in clinical trials and enhance market competitiveness.
See More
Allogene Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Allogene Therapeutics reported a Q1 2026 GAAP EPS of -$0.18, beating expectations by $0.01, indicating some improvement in financial management despite ongoing losses.
- Expense Structure: General and administrative expenses totaled $14.1 million in Q1, including $5.6 million in non-cash stock-based compensation, reflecting the company's ongoing investment in talent attraction and retention, which may impact future profitability.
- Cash Position: As of March 31, 2026, the company had $266.9 million in cash, cash equivalents, and investments, ensuring sufficient operational funding for the coming months to support its R&D and market expansion plans.
- Stock Offering Plan: Allogene Therapeutics announced a $175 million stock offering at $2 per share, a move that will provide additional funding to help the company remain competitive in the fast-paced biopharmaceutical market.
See More
Allogene Therapeutics Announces $175 Million Stock Offering
- Earnings Announcement: Allogene Therapeutics is set to release its Q1 earnings on May 13th after market close, with consensus EPS estimate at -$0.18 and revenue at $1.82 million, and exceeding these estimates could bolster market confidence.
- Historical Performance: Over the past year, Allogene has beaten EPS and revenue estimates 50% of the time, indicating a certain level of competency in managing market expectations, and the upcoming earnings report will significantly influence investor sentiment regarding future growth.
- Analyst Estimate Revisions: In the last three months, Allogene's EPS estimates have seen two upward revisions with no downward adjustments, suggesting increased market confidence in the company's future profitability, which could positively impact its stock price.
- Stock Offering Announcement: Allogene Therapeutics has announced a $175 million stock offering at $2 per share, which not only provides funding to support its R&D efforts but may also affect its shareholder structure and market performance.
See More
Allogene Showcases CAR T Therapy Potential at AACR Meeting
- Preclinical Evaluation: Allogene presented its preclinical evaluation of BCMA/CD70 dual-targeting CAR T cells for high-risk multiple myeloma at the AACR meeting, indicating potential new treatment options for patients in cancer therapy.
- Technology Expansion: The company plans to extend its Dagger® technology into autoimmune diseases, utilizing a gene-edited dual-targeting CAR T approach aimed at reducing the need for chemotherapy-based lymphodepletion, thereby enhancing treatment durability and safety.
- Future Outlook: Allogene's CAR T therapy aims to enhance accessibility through on-demand availability, safety, and simplicity, potentially transforming the treatment landscape for cancer and autoimmune diseases in the future.
- Industry Leadership: Allogene is positioned as a leader in the evolution of autologous cell therapies, leveraging extensive experience in hematologic and solid tumors to address the growing patient demand and drive advancements in biologic manufacturing scale.
See More
Allogene Publishes Preclinical Data for ALLO-329 in Autoimmune Diseases
- Dual Targeting Approach: ALLO-329 demonstrates significant enhancement of CAR T cell expansion and persistence by simultaneously targeting CD19+ B cells and CD70+ T cells in autoimmune disease models, indicating its potential in treating conditions like systemic lupus erythematosus.
- Clinical Trial Progress: The ongoing Phase 1 RESOLUTION trial is actively enrolling patients, with initial data expected in June 2026, showcasing the product's prospects across various autoimmune diseases.
- FDA Fast Track Designation: ALLO-329 has received three Fast Track Designations from the FDA for the treatment of lupus, myositis, and scleroderma, highlighting its importance and potential market opportunities in clinical development.
- Manufacturing Advantages: The development of ALLO-329 integrates CRISPR technology and Dagger® technology, aiming to reduce or eliminate the need for conventional lymphodepletion, thereby enhancing treatment accessibility and patient tolerability, which could become a critical competitive differentiator in the cell therapy space.
See More
Allogene Therapeutics Prices $175M Public Offering of Common Stock
- Offering Size: Allogene Therapeutics has priced an underwritten public offering of 87.5 million shares at $2.00 per share, expecting gross proceeds of $175 million, which will support clinical trials and R&D initiatives.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 13.13 million shares, providing flexibility that could enhance the company's liquidity and market confidence.
- Use of Proceeds: The net proceeds from the offering will fund general corporate purposes, including clinical trials, R&D, administrative costs, and capital expenditures, thereby laying a foundation for the company's long-term growth.
- Market Reaction: Following the public offering announcement, Allogene's stock price dropped over 4% during after-market trading on Tuesday, reflecting a cautious market sentiment that may impact investor confidence.
See More
Allogene Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: In a 24-patient analysis, cema-cel achieved a 58.3% MRD clearance rate compared to 16.7% in the observation arm, representing a significant 41.6% absolute difference, indicating a clear therapeutic advantage that could drive future clinical applications.
- Improved Financial Position: As of March 31, the company had $266.9 million in cash and cash equivalents, and in April, it raised approximately $200.4 million through a public offering, extending its cash runway into Q1 2029, thereby enhancing financial flexibility for R&D.
- Increased Expense Guidance: The forecast for operating cash expenses in 2026 has been raised from approximately $150 million to $165 million, with GAAP operating expenses expected to rise from $210 million to $225 million, reflecting confidence in future R&D investments while potentially impacting short-term financial performance.
- Safety and Tolerability: Management emphasized that no CRS, ICANS, or treatment-related hospitalizations were observed in ALLO-329 treatments, indicating feasibility in outpatient settings, which may attract more patients to participate in clinical trials and enhance market competitiveness.
See More
Allogene Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Allogene Therapeutics reported a Q1 2026 GAAP EPS of -$0.18, beating expectations by $0.01, indicating some improvement in financial management despite ongoing losses.
- Expense Structure: General and administrative expenses totaled $14.1 million in Q1, including $5.6 million in non-cash stock-based compensation, reflecting the company's ongoing investment in talent attraction and retention, which may impact future profitability.
- Cash Position: As of March 31, 2026, the company had $266.9 million in cash, cash equivalents, and investments, ensuring sufficient operational funding for the coming months to support its R&D and market expansion plans.
- Stock Offering Plan: Allogene Therapeutics announced a $175 million stock offering at $2 per share, a move that will provide additional funding to help the company remain competitive in the fast-paced biopharmaceutical market.
See More
Allogene Therapeutics Announces $175 Million Stock Offering
- Earnings Announcement: Allogene Therapeutics is set to release its Q1 earnings on May 13th after market close, with consensus EPS estimate at -$0.18 and revenue at $1.82 million, and exceeding these estimates could bolster market confidence.
- Historical Performance: Over the past year, Allogene has beaten EPS and revenue estimates 50% of the time, indicating a certain level of competency in managing market expectations, and the upcoming earnings report will significantly influence investor sentiment regarding future growth.
- Analyst Estimate Revisions: In the last three months, Allogene's EPS estimates have seen two upward revisions with no downward adjustments, suggesting increased market confidence in the company's future profitability, which could positively impact its stock price.
- Stock Offering Announcement: Allogene Therapeutics has announced a $175 million stock offering at $2 per share, which not only provides funding to support its R&D efforts but may also affect its shareholder structure and market performance.
See More
Allogene Showcases CAR T Therapy Potential at AACR Meeting
- Preclinical Evaluation: Allogene presented its preclinical evaluation of BCMA/CD70 dual-targeting CAR T cells for high-risk multiple myeloma at the AACR meeting, indicating potential new treatment options for patients in cancer therapy.
- Technology Expansion: The company plans to extend its Dagger® technology into autoimmune diseases, utilizing a gene-edited dual-targeting CAR T approach aimed at reducing the need for chemotherapy-based lymphodepletion, thereby enhancing treatment durability and safety.
- Future Outlook: Allogene's CAR T therapy aims to enhance accessibility through on-demand availability, safety, and simplicity, potentially transforming the treatment landscape for cancer and autoimmune diseases in the future.
- Industry Leadership: Allogene is positioned as a leader in the evolution of autologous cell therapies, leveraging extensive experience in hematologic and solid tumors to address the growing patient demand and drive advancements in biologic manufacturing scale.
See More
Allogene Publishes Preclinical Data for ALLO-329 in Autoimmune Diseases
- Dual Targeting Approach: ALLO-329 demonstrates significant enhancement of CAR T cell expansion and persistence by simultaneously targeting CD19+ B cells and CD70+ T cells in autoimmune disease models, indicating its potential in treating conditions like systemic lupus erythematosus.
- Clinical Trial Progress: The ongoing Phase 1 RESOLUTION trial is actively enrolling patients, with initial data expected in June 2026, showcasing the product's prospects across various autoimmune diseases.
- FDA Fast Track Designation: ALLO-329 has received three Fast Track Designations from the FDA for the treatment of lupus, myositis, and scleroderma, highlighting its importance and potential market opportunities in clinical development.
- Manufacturing Advantages: The development of ALLO-329 integrates CRISPR technology and Dagger® technology, aiming to reduce or eliminate the need for conventional lymphodepletion, thereby enhancing treatment accessibility and patient tolerability, which could become a critical competitive differentiator in the cell therapy space.
See More
Allogene Therapeutics Prices $175M Public Offering of Common Stock
- Offering Size: Allogene Therapeutics has priced an underwritten public offering of 87.5 million shares at $2.00 per share, expecting gross proceeds of $175 million, which will support clinical trials and R&D initiatives.
- Underwriter Option: The underwriters have a 30-day option to purchase an additional 13.13 million shares, providing flexibility that could enhance the company's liquidity and market confidence.
- Use of Proceeds: The net proceeds from the offering will fund general corporate purposes, including clinical trials, R&D, administrative costs, and capital expenditures, thereby laying a foundation for the company's long-term growth.
- Market Reaction: Following the public offering announcement, Allogene's stock price dropped over 4% during after-market trading on Tuesday, reflecting a cautious market sentiment that may impact investor confidence.
See More
